A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes.
Mar 22 2024Mary Ann Liebert, Inc. A new study in the peer-reviewed journal Diabetes Technology & Therapeutics evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes.
Tirzepatide is approved for managing type 2 diabetes. It improves glucose control, facilitates weight loss, and improves cardiovascular disease outcomes. Satish Garg, MD, from the University of Colorado Denver, and coauthors, compared a group of adults with type 1 diabetes who were prescribed tirzepatide to a control group of adults with type 1 diabetes who were not using any weight-loss medication. The investigators reported significantly larger declines in body mass index and weight in the treated group compared to controls. HbA1c decreased in the treated group as early as three months and was sustained through a one-year follow-up.
"We conclude that tirzepatide facilitated an average 18.5% weight loss and improved glucose control in patients with T1D at one year," stated the investigators. Related Stories"Most of the patients with diabetes, both type 1 diabetes and T2D are either overweight or obese in the United States and Western Europe," state Satish Garg, MD, and coauthors of an accompanying Editorial. The newer therapies for diabetes, which are known to not only improve glucose control but also cause significant weight loss and improve cardiovascular disease and diabetic kidney disease are currently not approved in the U.S. for use in type 1 diabetes.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers use algorithm to provide innovative insights into the heterogeneity of type 2 diabetesA landmark study by the German Diabetes Center (DDZ), published in The Lancet Diabetes & Endocrinology, sheds new light on the heterogeneity of type 2 diabetes. The researchers have employed an innovative algorithm to stratify people with type 2 diabetes using routine data and thus visualize the metabolic diversity of diabetes.
Read more »
Study sheds new light on the heterogeneity of type 2 diabetesA landmark study by the German Diabetes Center (DDZ), published in The Lancet Diabetes & Endocrinology, sheds new light on the heterogeneity of type 2 diabetes.
Read more »
Study shows glucose levels affect cognitive performance in people with type 1 diabetes differentlyA new study led by researchers at McLean Hospital (a member of Mass General Brigham) and Washington State University used advances in digital testing to demonstrate that naturally occurring glucose fluctuations impact cognitive function in people with type 1 diabetes (T1D).
Read more »
Weight loss caused by common diabetes drug tied to 'anti-hunger' molecule in studyAn 'anti-hunger' molecule produced after vigorous exercise is responsible for the moderate weight loss caused by the diabetes medication metformin, according to a new study in mice and humans. The molecule, lac-phe, was discovered by Stanford Medicine researchers in 2022.
Read more »
Antibiotic dosing technology speeds recovery of ICU patients, study findsUniversity of Queensland researchers have used dosing software to accelerate the effects of antibiotics in patients being treated for sepsis in Intensive Care Units.
Read more »
Point-of-care therapeutics sensor could make automated dosing systems universalRice University synthetic biologists have found a way to piggyback on the glucose monitoring technology used in automated insulin dosing systems and make it universally applicable for the monitoring and dosing of virtually any drug.
Read more »